.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,725,884

« Back to Dashboard

Claims for Patent: 5,725,884

Title: Pharmaceutical excipient having improved compressibility
Abstract:A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from about 1 nanometer to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide.
Inventor(s): Sherwood; Bob E. (Amenia, NY), Hunter; Edward A. (Glenham, NY), Staniforth; John H. (Bath, GB2)
Assignee: Edward Mendell Co., Inc. (Patterson, NY)
Application Number:08/724,613
Patent Claims: 1. An aqueous slurry useful in the preparation of a compressible pharmaceutical excipient, comprising a mixture of microcrystalline cellulose and from about 0.1% to about 20% by weight silicon dioxide based on the weight of said microcrystalline cellulose, said silicon dioxide having an average primary particle size from about 1 nm to about 100 .mu.m, the solids content of said aqueous slurry being from about 0.5% to about 25% by weight.

2. A solid dosage form of a compressed mixture of from about 1% to about 99% of an excipient comprising a particulate agglomerate of coprocessed microcrystalline cellulose and from about 0.1% to about 20% by weight silicon dioxide, the microcrystalline cellulose and silicon dioxide being in intimate association with each other, said silicon dioxide portion of said agglomerate being derived from a silicon dioxide having an average primary particle size from about 1 nm to about 100 .mu.m, and from about 99% to about 1% of a therapeutically active ingredient.

3. The solid dosage form of claim 2, wherein the silicon dioxide portion of said agglomerate is derived from a silicon dioxide having an average primary particle size from about 5 .mu.m to about 50 .mu.m.

4. The solid dosage form of claim 2, wherein the silicon dioxide portion of said agglomerate is derived from colloidal silicon dioxide.

5. The solid dosage form of claim 4, which has been wet granulated prior to compression.

6. The solid dosage form of claim 2, which is incorporated into an oral dosage form.

7. A method of enhancing the compressibility of microcrystalline cellulose in wet granulation products, comprising:

(a) forming an aqueous slurry containing a mixture of microcrystalline cellulose and silicon dioxide having an average primary particle size from about 1 nm to about 100 .mu.m, the amount of silicon dioxide being from about 0.1% to about 20% relative to the amount of microcrystalline cellulose, by weight; and

(b) drying said slurry to obtain an excipient comprising a plurality of agglomerated particles of said microcrystalline cellulose in intimate association with said silicon dioxide.

8. The solid dosage form of claim 2, wherein said silicon dioxide portion of said agglomerate is derived from a silicon dioxide having an average primary particle size from about 5 nm to about 40 .mu.m.

9. The solid dosage form of claim 2, wherein said silicon dioxide is included in amount from about 0.1% to about 20% by weight, based on the weight of microcrystalline cellulose.

10. The solid dosage form of claim 2, wherein said silicon dioxide is present in an amount ranging from about 0.5% to about 10% by weight, based on the weight of said microcrystalline cellulose.

11. The composition of claim 2, wherein said silicon dioxide is included in an amount of from about 1.25% to about 5%, based on the weight of said microcrystalline cellulose.

12. The solid dosage form of claim 2, wherein said excipient particles have an average particle size of from about 10 .mu.m to about 1,000 .mu.m.

13. The solid dosage form of claim 2, wherein said excipient particles have an average particle size of from about 10 .mu.m to about 500 .mu.m.

14. The solid dosage form of claim 2, wherein said excipient particles have an average particle size of from about 30 .mu.m to about 250 .mu.m.

15. The solid dosage form of claim 2, wherein said excipient particles have a moisture content from about 0.5% to about 15%.

16. The solid dosage form of claim 2, wherein said excipient particles further comprise a member of the group consisting of non-silicon metal oxides, starches, starch derivatives, surfactants, polyalkylene oxides, celluloses, cellulose ethers, cellulose esters and mixtures thereof.

17. The solid dosage form of claim 2, wherein said silicon dioxide portion of said agglomerate is derived from a silicon dioxide having a surface area from about 10 m.sup.2 /g to about 500 m.sup.2 /g.

18. The solid dosage form of claim 2, wherein said silicon dioxide portion of said agglomerate is derived from a silicon dioxide having a surface area from about 175 m.sup.2 /g to about 350 m.sup.2 /g.

19. The solid dosage form of claim 2, wherein said excipient has a bulk density from about 0.2 g/ml to about 0.6 g/ml.

20. The solid dosage form of claim 2, wherein said excipient has a bulk density from about 0.35 g/ml to about 0.55 g/ml.

21. The solid dosage form of claim 2, prepared by a process comprising the steps of

(a) forming an aqueous slurry containing a mixture of microcrystalline cellulose and silicon dioxide having a particle size from about 1 nm to about 100 .mu.m, the amount of silicon dioxide being from about 0.1% to about 20% relative to the amount of microcrystalline cellulose, by weight;

(b) drying said slurry to obtain an excipient comprising a plurality of agglomerated particles of said microcrystalline cellulose in intimate association with said silicon dioxide;

(c) mixing an active ingredient with said excipient in a ratio from about 1:99 to about 99:1;

(d) incorporating said mixture obtained in step (c) into a plurality of solid dosage forms.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc